Truist Securities Maintains Buy on IDEAYA Biosciences, Raises Price Target to $60

Benzinga · 6d ago
Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $59 to $60.